Actively Recruiting
Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction
Led by Peking University People's Hospital · Updated on 2024-01-18
300
Participants Needed
1
Research Sites
207 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A research investigation into the efficacy of digital Polymerase Chain Reaction (dPCR) for monitoring measurable residual disease (MRD) during allogeneic hematopoietic stem cell transplantation, with a focus on predicting relapse in patients diagnosed with leukemia, myelodysplastic syndromes (MDS), and related hematological conditions.
CONDITIONS
Official Title
Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have at least one fusion gene or blood tumor-associated mutation detected at diagnosis by NGS or real-time PCR for post-transplant MRD monitoring
- Have experienced neutrophil engraftment
- Have received at least one MRD monitoring by digital PCR after stem cell transplant
You will not qualify if you...
- Relapsed or died before the first digital PCR monitoring
- Have only mutations in DNMT3A, TET2, and ASXL1 (DTA mutations) or only germline mutations
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044
Actively Recruiting
Research Team
M
Meng Lv, M.D,Ph.D
CONTACT
Y
Ya-zhen Qin, Ph.D
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here